{
  "docId": "019de076-48c2-7315-bf77-72d2721572a4",
  "docSlug": "9ba2b11c98152a86fe4ad3555ff50f91",
  "documentTitle": "Immatics | Investor Presentation Deck | 75 slides",
  "authorId": "immatics",
  "authorName": "Immatics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 75,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a matrix structure to define the patient population and market opportunity.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-48c2-7315-bf77-72d2721572a4/24",
  "deckHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4",
  "deckJsonHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4.json",
  "deckAnchorHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.94,
        "x": 0.06,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "CPI: Checkpoint inhibitor; 1 Based on annual mortality of ~7,700 cutaneous melanoma patients in the US... 2 Based on annual mortality of ~800 uveal melanoma patients in the US... Data cut-off Sep 30, 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9792cb09-ac3b-4995-837e-2ff1d76b5f44",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.48,
        "x": 0.46,
        "y": 0.36
      },
      "kind": "framework",
      "text": "Matrix comparing Patient Population (2L+) vs IMA203 Opportunity for Cutaneous and Uveal Melanoma",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45d5a43c-8662-4c04-bd45-e47a4c6cd5a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.38,
        "x": 0.08,
        "y": 0.235
      },
      "kind": "list",
      "text": "Clinically and Commercially Attractive Features of IMA203: ≥95% of cutaneous melanoma patients are PRAME-positive; Well tolerated; Promising anti-tumor activity; Leukapheresis as source; Short manufacturing time; Low dose IL-2",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cdd46acd-9461-42d1-9998-ffaaeebf9b24",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "IMA203 GEN1 in Melanoma Targeted to Enter Registration-Enabling Phase 2 Trial in 2024",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e2c1aa9-ef5b-4016-93d3-4a7a29431e11",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "8e69a1e9-116c-4bd2-86cf-6ab41ca6bbe9",
      "evidence": "Matrix comparing Patient Population (2L+) vs IMA203 Opportunity for Cutaneous and Uveal Melanoma",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "matrix-2x2",
      "slug": null,
      "matchId": "87e72233-c155-4dda-a208-b305152a4bae",
      "evidence": "The right side of the slide uses a 2x2 grid to segment patient populations and market opportunities.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 33,
      "from": 16,
      "beatId": "e53f0bdd-f989-4e54-a22e-36140cd1c7e7",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The traction is presented in the traction and appendix data sections.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 20,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "89016a77-dafb-4a09-a082-b702ab9d3e72",
      "evidence": "The loop is visible in the section on delivering a meaningful benefit to patients with an unmet medical need.",
      "position": 0,
      "objective": "Highlight the unmet medical need",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}